Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy
European Journal of Pharmacology · 2025-11 · 1006 · 178146
DOI: 10.1016/j.ejphar.2025.178146 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025-11. Verfasst von Patricia Sánchez-Jiménez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigaciones Sanitarias la Princesa (IIS-IP), Universidad Au…. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Gene Expression Profiling, Drug Repositioning, Drug Resistant Epilepsy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: San Pablo CEU University, Consejería de Educación e Investigación, Instituto de Salud Carlos III.
Abstract (Originalsprache)
BACKGROUND: Epilepsy drug treatments fail in 25-30 % of patients, leading to drug resistance. Temporal lobe epilepsy is the most prevalent subtype associated with drug resistance. Classical drug discovery is a long and extremely costly process with a high failure rate in clinical trials. Drug repurposing is a more cost- and time-effective strategy. Hence, the main objective of this study is to propose drug candidates for the treatment of drug-resistant temporal lobe epilepsy (DR-TLE) through drug repurposing based on transcriptomic profiling. METHODS: Total RNA-sequencing (RNA-Seq) was performed on 45 formalin-fixed paraffin-embedded (FFPE) hippocampi of DR-TLE patients and 36 FFPE hippocampi of post-mortem biobank donors. RNA-Seq was carried out on an Illumina NovaSeq 6000 platform in 100bp paired-end. Drug repurposing based on transcriptomic analysis top candidates was performed against these databases: Pandrugs2, PharmOmics, DGIdb, ToppGene, L1000CDS2 and Connectivity Map. RESULTS: We identified 887 genes differentially expressed between DR-TLE patients and post-mortem controls. We observed 74 potential drug candidates in at least two independent databases. Of these, we selected only the 11 which can cross the blood-brain barrier: cobimetinib, panobinostat, melphalan, rucaparib, alectinib, ponatinib, danazol, carboplatin, vandetanib, erlotinib, and gefitinib. After analyzing their mechanisms to modulate epileptogenesis, their safety and efficacy profiles from previous publications, we provide a list of the top 5 candidates. CONCLUSION: Based on differential RNA-Seq profiling, we therefore propose erlotinib, danazol, rucaparib, ponatinib, and panobinostat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigaciones Sanitarias la Princesa (IIS-IP), Universidad Autónoma de Madrid, Madrid, Spain; NIMGenetics Genómica y Medicina S.L.,…
- Genetic & Molecular Epidemiology Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain.
- Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Spain.
- Institut d'Investigació Sanitària Pere Virgili (IISPV), Bioinformatics Platform, Reus, Tarragona, Spain.
- Clinical Analysis Department, Hospital Universitario de La Princesa, Madrid, Spain.
- GenomCore S.L., Barcelona, Spain.
Förderung
- San Pablo CEU University
- Consejería de Educación e Investigación
- Instituto de Salud Carlos III
- Community of Madrid
Zitieren
APA
Sánchez-Jiménez, P., Alonso-Guirado, L., Cerrada-Gálvez, L., Elizalde-Horcada, M., Granero-Cremades, I., Maietta, P., Gómez-Martín, A., Abad-Santos, F., Torres-Díaz, C. V., de Toledo, M., Frade-Porto, N., Gonzalez-Tarno, P., Pulido, P., & Ovejero-Benito, M. C. (2025). Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy. European Journal of Pharmacology, 1006, 178146. https://doi.org/10.1016/j.ejphar.2025.178146
Vancouver
Sánchez-Jiménez P, Alonso-Guirado L, Cerrada-Gálvez L, Elizalde-Horcada M, Granero-Cremades I, Maietta P, et al. Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy. European Journal of Pharmacology. 2025;1006:178146. doi:10.1016/j.ejphar.2025.178146
BibTeX
@article{SnchezJimnez2025,
author = {Sánchez-Jiménez, Patricia and Alonso-Guirado, Lola and Cerrada-Gálvez, Laura and Elizalde-Horcada, Marcos and Granero-Cremades, Inmaculada and Maietta, Paolo and Gómez-Martín, Antonio and Abad-Santos, Francisco and Torres-Díaz, Cristina Virginia and de Toledo, Maria and Frade-Porto, Natalia and Gonzalez-Tarno, Patricia and Pulido, Paloma and Ovejero-Benito, María C},
title = {Transcriptomic profiling unveils novel therapeutic options for drug-resistant temporal lobe epilepsy},
journal = {European Journal of Pharmacology},
year = {2025},
volume = {1006},
pages = {178146},
doi = {10.1016/j.ejphar.2025.178146}
}
EUVIMED